Develops drugs for cancer and rare diseases.
Dec 2025Revenue $58.7B/yrExpenses $45.0B/yr
No trend
Figures by year
Is Astrazeneca profitable?
Yes. In the 12 months to Dec 2025, revenue was $58.7B and expenses $45.0B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $58.7B | $45.0B | $13.7B |
| Dec 2024 | $54.1B | $44.1B | $10.0B |
| Dec 2023 | $45.8B | $37.6B | $8.19B |
| Dec 2022 | $44.4B | $40.6B | $3.76B |
| Dec 2021 | $37.4B | $36.4B | $1.06B |
| Dec 2020 | $26.6B | $21.5B | $5.16B |
| Dec 2019 | $24.4B | $21.5B | $2.92B |
| Dec 2018 | $22.1B | $18.7B | $3.39B |
| Dec 2017 | $22.5B | $18.8B | $3.68B |
| Dec 2016 | $23.0B | $18.1B | $4.90B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.